Nelson Advisors: European HealthTech M&A Hotspots for 2027
European healthtech is heading into 2027 with more buyers, more motivated sellers and a clearer regulatory calendar than at any point since 2021. Three forces are converging: a private equity industry that has raised record healthcare funds and now has to deploy and exit them; strategic acquirers who have decided that buying AI and data capability is faster than building it; and a regulatory clock, led by the European Health Data Space (EHDS), that turns interoperability from a nice-to-have into a purchasing criterion for every hospital, clinic and pharmacy in the EU.
The numbers behind that setup are worth pausing on. Global healthtech M&A logged 149 deals in Q1 2026 alone, on pace to beat 2025's full-year count of 555, with private equity accounting for roughly a third of transactions and disclosed value of $22.7 billion already approaching 2025's full-year total. In Europe specifically, sponsor buyouts in healthcare rose sharply through 2025 to a record volume, surpassing the 2021 peak, even as overall healthcare deal counts contracted amid macro uncertainty. That combination, fewer but larger and more sponsor-led deals, is the signature of a market that has finished its post-2021 reset and is now consolidating around scaled, cash-generative platforms.
The character of the buyer has changed too. In 2021, the marginal acquirer was a growth-stage venture fund paying revenue multiples for a promise. In 2026, it is a buy-and-build platform owned by a mid-market sponsor, a listed clinical-software vendor with an AI gap to fill, or a US strategic looking to Europe for cheaper, CE-marked technology and multilingual distribution. Deals announced in the first half of 2026 show all three at once: Hims & Hers paying up to $1.15 billion for Eucalyptus to buy telehealth scale in the UK, Germany and beyond; RadNet's DeepHealth acquiring Paris-based Gleamer; and Sectra folding Lithuanian autonomous-radiology pioneer Oxipit into its enterprise imaging stack.
This post picks the 10 markets and sub-markets where we expect that buyer interest to concentrate in 2027. The selection is deliberately weighted toward European-specific dynamics rather than a translation of US themes: reimbursement pathways that exist here and nowhere else (Germany's DiGA, France's PECAN), procurement moments that only a national health system creates (NHS England's electronic patient record programme, national ambient-scribe frameworks), and regulatory deadlines that only apply in the EU (EHDS implementing acts in March 2027, the AI Act's high-risk obligations, the still-grinding MDR transition). For each market we set out why buyers want in, who the likely acquirers are, what kinds of assets will trade, and what the pricing conversation is likely to look like.
A caveat before we start. Forecasting M&A a year out is partly about spotting where the money already is and partly about guessing where the next wave of consolidation breaks. We have tried to anchor each pick in transactions that have actually closed or been announced in 2025 and 2026, and to be candid where the thesis depends on things that have not yet happened. Figures quoted from advisers and data providers are their estimates, not ours.
1. Ambient clinical AI and documentation
Ambient scribing is the most crowded, fastest-moving and most obviously over-supplied category in European healthtech, which is precisely why it will generate a disproportionate share of 2027's deal flow. The Netherlands alone has more than 20 vendors selling AI scribes into a market of roughly 18 million people. Multiply that across Germany, France, the Nordics, Spain and the UK and you have well over a hundred companies chasing a category that, at scale, supports perhaps five or six pan-European winners. The arithmetic of that gap is the M&A thesis.
Why buyers want in. The technology has crossed from pilot to procurement. Norway ran a single national tender worth around €15 million at the end of 2025, selecting four to five vendors for a framework any hospital can draw on, and the tender explicitly required vendors to be capable of CE-marking their product as a medical device. NHS England has published national guidance on ambient voice technology, and the UK's MHRA now treats AI scribes as software with a medical intended purpose. That regulatory hardening matters for deal-making in two ways. It raises the cost of staying independent, because Class I self-certification is cheap but the move toward decision support pushes vendors toward Class IIa and notified-body review, which is neither cheap nor fast. And it makes the survivors more valuable, because a CE-marked, MDR-compliant scribe with a national framework contract is a regulated asset with a moat, not a wrapper around a foundation model.
The first deals have already happened. Sweden's Tandem Health bought Dutch rival Juvoly around the turn of 2026, which the market read as Europe's first scribe-on-scribe consolidation. That is the template we expect to repeat throughout 2027: the two or three best-funded European scribes (Tandem, Corti, Nabla and Tortus are the names most often mentioned) rolling up country leaders to buy language coverage, local EHR integrations and reference customers, rather than building each market from scratch. Distribution matters more than model quality here, since the underlying speech and summarisation models are increasingly commoditised.
Who the acquirers are. Three buyer groups will compete for the same assets. First, the pan-European scribe consolidators themselves, using fresh venture capital as acquisition currency. Second, the incumbent practice-management and EHR vendors, who need a native ambient layer to defend their installed base against standalone tools; CompuGroup Medical, Dedalus, Doctolib, Nexus and the UK GP-system vendors all fall into this category, and every one of them has either shipped or announced a scribe. Third, the global platforms, most obviously Microsoft with Dragon Copilot and the US scale players such as Abridge, for whom a European acquisition solves language, data-residency and integration problems in one move. Financial sponsors will mostly participate indirectly, by backing the consolidators, because pure-play scribes are still too early and too price-competitive for a leveraged buyout.
What the pricing looks like. Expect a barbell. Sub-scale scribes with under €2 million of ARR will trade for modest sums or be acqui-hired. The handful with national contracts, MDR pathways and multi-country deployment will command growth-software multiples that look expensive on current revenue but reasonable on 2028 run-rate. The endpoints of the category are already converging: documentation is becoming the entry point for coding, ordering and decision support, so acquirers are paying for the workflow position, not the note.
What could go wrong. Pricing pressure is real; productivity gains measured in trials are modest at one to two minutes per consultation, so budget holders may push scribes toward a bundled feature rather than a paid product. If the incumbents bundle successfully, standalone valuations compress and 2027 becomes a year of distressed rather than triumphant consolidation. Either way, deals happen.
2. Radiology and diagnostic imaging AI
Imaging AI is the one clinical-AI category in Europe where the consolidation wave has already broken, and 2027 will be about the second and third rows of the market being absorbed after the leaders went in 2026. Two deals in a single week of March 2026 set the tone. RadNet's DeepHealth acquired Gleamer, the Paris-based X-ray and routine-imaging specialist with more than 700 customer contracts in 44 countries, ARR growing at over 90% a year since 2022 and an expected $30 million ARR in 2026. Days later, Sectra agreed to buy Oxipit, the Lithuanian company whose ChestLink holds a CE Class IIb certification for autonomous reporting of normal chest X-rays, the first product of its kind in Europe.
Why buyers want in. The demand driver is structural rather than cyclical. Europe has a chronic radiologist shortage, imaging volumes grow faster than headcount, and health systems have started paying for AI that demonstrably shortens reporting queues rather than AI that merely flags findings. The $1 billion sale of Everlight Radiology to Radiology Partners in August 2026, a doubling of the value Livingbridge paid in 2021, shows what a services platform with an AI overlay can be worth. Meanwhile, Bayer's withdrawal from the AI marketplace business in 2025 removed one distribution channel and pushed algorithm developers toward acquirers that own the PACS, the scanner or the reading service.
Who the acquirers are. The buyer set is unusually broad. Enterprise-imaging and PACS vendors (Sectra, Agfa HealthCare, Philips, Siemens Healthineers, GE HealthCare) want native AI to defend against platform aggregators. Teleradiology and outsourced-reading groups (Radiology Partners via Everlight, Medica, Unilabs, Telemedicine Clinic) want AI to lift radiologist throughput, and are now large enough to buy rather than license. US clinical-AI aggregators (Aidoc, DeepHealth) want CE-marked products and European reference sites. And a growing class of sponsor-backed imaging-services platforms across Germany, Spain, Italy and the Nordics treats AI as a margin lever inside a buy-and-build. Financial buyers will mostly show up at the services end, buying the reading groups and diagnostic-centre chains that then acquire algorithm companies as bolt-ons.
What will trade. We expect three asset types to change hands in 2027. Single-indication algorithm companies with CE marks but limited distribution, which sell for capability and regulatory files rather than revenue. Multi-modality platforms with recurring revenue in the €10 million to €40 million range, which are the natural targets for PACS vendors and US aggregators. And the first European teleradiology groups with proprietary AI, which will attract sponsor interest at the £200 million-plus level. Foundation-model radiology startups, several of which sit in London and Zurich, are the wildcard: they will either raise large rounds or be absorbed by a scanner manufacturer wanting a generalist model.
Pricing. Gleamer's disclosed metrics give a rare reference point: a high-growth, cloud-first imaging AI business at roughly $30 million of ARR was worth enough to a listed strategic to justify a global-leadership claim. Sub-scale peers will not get that multiple, but the existence of a public benchmark tends to anchor seller expectations for a year or more. The MHRA's international reliance framework, live from 2026, also lowers the cost of taking a CE-marked product into the UK, which raises the value of European regulatory files to any buyer with UK ambitions.
What could go wrong. Reimbursement remains the gating factor. Outside a few national programmes, hospitals still pay for imaging AI from IT rather than clinical budgets, and that ceiling limits ARR growth for standalone vendors. If procurement stays fragmented, the category consolidates faster but at lower prices, which is good news for buyers and sobering for late-stage venture investors.
3. Electronic patient records and hospital core systems
The unglamorous end of the market is where the largest cheques will be written in 2027. Europe's hospital-IT landscape is a mosaic of national and regional champions: TPP, System C and EMIS in the UK; Cegedim, Maincare and Softway Medical in France; CompuGroup Medical, Nexus and Meierhofer in Germany; Dedalus, Engineering and GPI in Italy; DIPS in Norway; Cambio in Sweden; Systematic in Denmark; Comarch and Asseco in Poland. Almost none of them is big enough to fund an EHDS-grade interoperability rebuild and a generative-AI layer on their own, and several are already in sponsor hands with holding periods running long.
Why buyers want in. Two clocks are ticking. The first is regulatory: EHDS makes the Commission's common specifications for EHR systems applicable from March 2027, with the first mandatory exchange of patient summaries and e-prescriptions across the EU due in March 2029. Vendors that cannot demonstrate a credible EHDS roadmap will lose tenders from 2027 onward, and hospitals that suspect their vendor cannot deliver will start procurement early rather than late. The second clock is national: NHS England has committed to every trust having an EPR, and the frontline-digitisation programme is producing a steady cadence of trust-level procurements in which Dedalus, System C, Oracle Health, Epic and Meditech compete for multi-year contracts. Both dynamics reward scale and punish sub-scale, which is the definition of a consolidation trigger.
The sponsors are already in position. Dedalus has been Ardian-owned since 2016, has bulked up through the Agfa HealthCare IT and DXC healthcare software acquisitions, and is approaching €1 billion of revenue; a decade-long hold points to a 2027 or 2028 liquidity event, whether through a sale to another sponsor, a partial IPO or a strategic combination. CompuGroup Medical was taken private by CVC in 2025 and Nexus by TA Associates the same year, which means two of Germany's three major hospital-IT vendors now have owners with explicit buy-and-build mandates and five-year timelines. Expect both to be active acquirers of specialist modules (laboratory, pathology, medication management, patient-portal and scheduling tools) across the DACH region, Benelux and the Nordics throughout 2027.
Who else is buying. Oracle Health and Epic remain the US shadow over every European EPR conversation, but both grow organically in Europe rather than by acquisition, so their effect on M&A is indirect: they win the large teaching-hospital tenders and leave the mid-market to the Europeans, who then consolidate to compete. Infrastructure-software groups and IT-services companies (Atos-successor entities, Sopra Steria, Tietoevry, Engineering) see hospital core systems as sticky, government-backed recurring revenue and periodically bid for the regional champions. And the large healthcare-services groups such as Fresenius, Ramsay Santé and Mediclinic occasionally take strategic stakes in their own IT suppliers to secure roadmap control.
What will trade. The most likely 2027 transactions are secondary buyouts of mid-sized national vendors with €50 million to €300 million of revenue, bolt-ons of specialist clinical modules into the sponsor-backed platforms, and carve-outs of healthcare software divisions from diversified IT groups, following the pattern set by Dedalus's purchase of the Lutech healthcare software division. The single biggest potential deal is a Dedalus exit, which would be the largest European healthtech transaction of the year by some distance.
Pricing. Hospital-IT trades on EBITDA rather than revenue, typically in the mid-teens for scaled, cash-generative platforms with high public-sector renewal rates, lower for businesses with legacy on-premise estates and cloud-migration liabilities. The differentiator in 2027 will be how much of the base is already on a cloud-hosted, FHIR-native product; anything that requires a re-platforming will be discounted heavily.
What could go wrong. Implementation risk is the enemy. High-profile EPR go-live failures in the NHS and elsewhere have made procurement boards cautious, and a couple of bad headlines in 2027 could delay tenders and push exits into 2028. National-security and data-sovereignty reviews of foreign acquisitions of health-record vendors are also becoming more common and can add six months to a process.
4. Health data, real world evidence and clinical trial technology
If ambient AI is the most crowded category and EPR the largest, health data is the one where 2027 timing is most precisely defined by regulation. The EHDS secondary-use regime, the part of the law that lets researchers, regulators and companies apply for access to pseudonymised health data through national health data access bodies, starts to apply for most data categories in March 2029, with the Commission's implementing acts on access applications, secure processing environments and data-quality labelling due by March 2027. That gives every pharma company, CRO and data vendor exactly two years from the rules being published to the infrastructure being live, and 2027 is when they will buy the capability rather than build it.
Why buyers want in. Europe's real-world data has always been richer than the US's (single-payer registries, national cancer and cardiovascular databases, decades of longitudinal primary-care records) and harder to use, because it sits behind 27 different legal regimes. EHDS promises to standardise the access route through a single HealthData@EU infrastructure and national access bodies, which converts a patchwork into an addressable market. The companies that already operate federated-analytics platforms, trusted research environments, natural-language extraction from clinical notes and consented-data networks are the ones that will be able to plug into that infrastructure on day one, and they will be priced accordingly.
Who the acquirers are. Life-sciences data and evidence groups are the natural strategic buyers: IQVIA, ICON, Parexel, Veeva, Flatiron and the Oracle life-sciences business all have European RWE ambitions and have bought European data assets before. The large European CROs and evidence consultancies (Cegedim Health Data, IQVIA's European arm, Evidera) will look for country-specific datasets and extraction technology. Sponsors already own several of the platform businesses, and a wave of secondary sales is likely as funds raised in 2019 to 2021 reach the end of their hold periods. There is also a plausible role for the hospital-IT vendors described above, who sit on the primary data and could vertically integrate into secondary-use tooling, as Dedalus has already signalled through its clinical-trial partnerships.
What will trade. Four asset types stand out. Federated-analytics and trusted-research-environment vendors, which are the technical core of EHDS-style secure processing environments and will be acquired by anyone who wants to be a national access body's supplier. Clinical NLP and structuring companies (Spain's Savana is the reference name) that turn free-text notes into research-grade data. Country-specific data networks with consented patient cohorts, especially in oncology, rare disease and cardiometabolic disease, where pharma demand is highest. And decentralised-trial and site-technology businesses, which are being folded into CRO platforms as trial designs move hybrid.
Pricing. This is a revenue-multiple category, and the multiples diverge sharply. Pure data-licensing businesses with pharma contracts trade at high single-digit revenue multiples because contracts are large and sticky. Software-only tooling with hospital customers trades lower unless it has a clear route into the EHDS infrastructure. Assets that combine data rights, extraction technology and an established relationship with a national access body will be the ones where bidding gets competitive.
What could go wrong. Implementation delay is the obvious risk: several member states are behind on building their access bodies, funding is uneven, and the Commission has been urging governments not to wait for the 2027 implementing acts. If the March 2029 date slips, some of the 2027 acquisition thesis slips with it. The other risk is political: opt-out rights for patients and restrictions on commercial use vary by country, and a restrictive interpretation in a large market such as Germany or France would reduce the addressable data pool that buyers are paying for.
5. Digital therapeutics and mental health platforms
Digital therapeutics is the category where consolidation is being driven as much by distress as by ambition, and 2027 is when the sorting finishes. Germany's DiGA programme, the world's first national reimbursement route for prescription apps, has created a real market: around 1.6 million activation codes had been redeemed by the end of 2025, roughly 695,000 of them in 2025 alone, with mental-health apps accounting for 27% of use. Statutory insurers spent around €234 million on DiGA in 2024. But of 72 apps ever approved, 15 have already been delisted and a growing number of makers are in financial difficulty. That is the profile of a market about to be rolled up.
Why buyers want in. Two changes in 2026 tilt the economics toward scaled owners. DiGA reform now ties at least 20% of price to measured outcomes, mandates outcomes monitoring and opens the scheme to Class IIb devices. Performance-linked pricing rewards companies with clinical-evidence machines and punishes single-app founders who cannot afford post-market studies; Class IIb eligibility invites more serious medtech and pharma players into the scheme. France's PECAN early-access route and the UK's evolving NICE digital pathways add a second and third market to the addressable base, so a DiGA-listed app with a French dossier is worth materially more than a German-only one. Mental health remains the largest indication and the one where waiting lists are politically toxic across every European health system, which sustains payer demand.
Who the acquirers are. Pharma is the most interesting new buyer. Companies with large CNS, metabolic and musculoskeletal franchises have begun treating digital therapeutics as around-the-pill services rather than curiosities, and the GLP-1 era has made behavioural and adherence software commercially relevant to the biggest drug launches in a generation. Health insurers, particularly the large German statutory funds and the private insurers in the UK and Switzerland, are buying or backing mental-health platforms to control cost and access. Sponsor-backed mental-health service providers (outpatient clinic chains, online therapy providers such as those built by the Nordic and DACH sponsors) are acquiring apps to blend digital and human care. And the surviving digital-therapeutics platform companies are consolidating peers to build multi-indication portfolios that spread the fixed cost of evidence generation.
What will trade. Expect a stream of small transactions: delisted or struggling DiGA makers selling to platforms for the value of their clinical evidence and BfArM files; multi-app portfolios changing hands between sponsors; and a small number of larger deals where an insurer or pharma company buys a scaled mental-health or metabolic platform outright. Online therapy providers that pair clinicians with software, rather than software alone, will command the best prices because their revenue is less exposed to reimbursement resets.
Pricing. Pure-software DTx businesses have been re-rated hard since 2021 and will trade on a mixture of revenue and evidence value, often at low single-digit multiples. Blended care providers with recurring insurer contracts trade higher, on EBITDA. Buyers will pay a premium for products with permanent DiGA listing, positive outcomes data from the new monitoring regime and reimbursement in at least two countries.
What could go wrong. Reimbursement is the whole game, and German health policy is under fiscal pressure; a tightening of DiGA price negotiation or a slow PECAN pipeline in France would strand many of the smaller companies without a buyer at any price. There is also a real risk that general-purpose AI assistants erode the perceived value of structured digital therapy in low-acuity mental health, which would move buyer interest toward regulated, clinician-supervised models and away from app-only ones.
6. Virtual care, telehealth and hospital at home
Virtual care in Europe is entering its second consolidation cycle, and this one is being led by profitable buyers rather than cash-burning ones. The 2021 vintage of telehealth roll-ups mostly ended in write-downs; the 2026 vintage is different because the acquirers are cash-generative consumer-health platforms, national provider groups and insurers who need digital front doors they can no longer justify building. The marker deal was Hims & Hers agreeing to pay up to $1.15 billion for Eucalyptus in February 2026, a transaction that bought the US company an established prescribing and pharmacy footprint in the UK and Germany. In the Nordics, Finland's Mehiläinen acquired Aleris to expand into Norway and Denmark, a provider-led consolidation that brings a fully digital care layer with it.
Why buyers want in. Three demand engines are running at once. The GLP-1 and consumer-prescribing boom has made online consultation and fulfilment a large, profitable category in Europe for the first time; the winners need licensed prescribing capability in each country, which is far quicker to buy than to build. National health systems are pushing care out of hospitals, with NHS England's neighbourhood-health model, Germany's hospital reform and the Nordic hospital-at-home programmes all creating demand for virtual-ward and remote-consultation infrastructure. And private insurers across the UK, Germany, Switzerland and Spain are bundling virtual GP and mental-health access into policies as a retention tool, which means they either buy the platform or pay a rising licence fee to somebody else's.
Who the acquirers are. Consumer-health platforms (Hims & Hers, and the European direct-to-consumer players now generating real margin from weight management and men's and women's health) will keep buying country-specific prescribing and pharmacy businesses. Provider groups with sponsor backing, of which Mehiläinen, Ramsay Santé, Medicover, Quirónsalud and the DACH clinic chains are the largest, buy telehealth to fill capacity and reach patients between visits. Insurers such as AXA, Allianz, Bupa and the large German private and statutory funds are strategic buyers of virtual primary care and mental-health platforms. And the sponsor-owned pan-European telehealth platforms that survived 2022 (the Kry/Livi and Doctolib-adjacent ecosystem, and the Zava-style online-doctor businesses) are themselves both consolidators and, increasingly, targets.
What will trade. Expect the cleanest deals to be in three places. Online prescribing and pharmacy businesses with a licence in each major European market, which trade on gross-margin and repeat-customer metrics like any consumer subscription. Virtual-ward and hospital-at-home technology vendors, particularly those with NHS or Nordic reference sites, which health-system-facing acquirers and medtech companies want as they push monitoring into the home. And specialist virtual clinics (dermatology, sexual health, fertility, menopause) that have reached profitability in one country and need a parent with the balance sheet to replicate elsewhere.
Pricing. Consumer-prescribing platforms will trade on EBITDA once profitable and on contribution margin before that; the Eucalyptus valuation demonstrated that a scaled, multi-market business can command more than one times its annualised gross revenue even after the 2022 reset. Health-system-facing virtual-care software will be priced like healthtech SaaS, on ARR with a discount for procurement cycle length.
What could go wrong. Regulation of online prescribing is tightening in several countries after high-profile concerns about GLP-1 access and compounding, and a restrictive turn in Germany or the UK would compress the consumer-health multiples that underpin the category. Antitrust scrutiny is also rising: the French Competition Authority's late-2025 fine against Doctolib for abuse of dominance is a reminder that dominant platforms cannot simply buy their way to further share in a single market.
7. Remote patient monitoring, connected devices and musculoskeletal digital care
Remote monitoring is where healthtech and medtech M&A overlap most, and where 2027 will see medtech balance sheets deployed against software targets. The category's defining 2026 transaction was Sword Health's $285 million acquisition of Kaia Health, which bought a US digital-musculoskeletal leader a permanent DiGA listing and a German reimbursement footprint. The logic, buying a European regulated asset to unlock a reimbursement channel that does not exist at home, is one we expect to see repeated across cardiology, respiratory, diabetes and oncology monitoring throughout 2027.
Why buyers want in. Chronic-disease management is moving out of the clinic in every European system because there is no workforce to keep it inside. Germany alone faces a projected clinical workforce shortfall of several hundred thousand by 2049, and similar arithmetic applies in the UK, France and Italy. Remote monitoring is the only scalable answer, and reimbursement is finally catching up: Germany's telemonitoring codes for heart failure, France's remote-monitoring framework, the NHS virtual-ward programme and the Nordic home-hospital models all now pay for connected care in some form. Medtech companies, meanwhile, have been told by investors since 2024 that they need recurring software revenue attached to their devices, and the fastest way to get it is to buy the monitoring platform their devices already feed.
Who the acquirers are. Large medtech is the dominant strategic buyer: Medtronic has said publicly that it intends to step up acquisitions, Philips and Siemens Healthineers are rebuilding their digital portfolios around monitoring, and the cardiac-rhythm, diabetes and respiratory device leaders all have European monitoring platforms on their target lists. Consumer-wearable companies are a second, newer buyer class; Oura's 2026 acquisition of Galen AI to bring medical records and wearable data together signals that wearables companies now want clinical-grade software. Health-system-facing platform vendors, including the hospital-IT groups described earlier, are buying monitoring modules to complete their care-outside-hospital offerings. And sponsors are active on the services side, backing home-care and nursing groups that then acquire monitoring technology as an operating lever.
What will trade. Three groups of assets look most likely to move in 2027. Disease-specific monitoring platforms with national reimbursement (heart failure, COPD, diabetes, oncology symptom tracking) that medtech will buy to attach to existing device franchises. Musculoskeletal and rehabilitation digital-care companies, where the Sword and Kaia deal has already established the price for a DiGA-listed asset and where several European players remain independent. And connected-device data-infrastructure businesses, the unglamorous middleware that ingests readings from hundreds of device types into a hospital's record, which every acquirer needs and few have.
Pricing. The Sword and Kaia benchmark suggests that a regulated European monitoring or digital-care asset with reimbursement in a major market can command a strategic premium well above what its standalone growth would justify, because the buyer is paying for a channel, not a product. Assets without reimbursement will trade at software multiples on ARR, with a discount for hardware exposure and device-refresh capital needs.
What could go wrong. Reimbursement is uneven and can be reversed, and monitoring programmes that cannot demonstrate reduced admissions will lose funding when health budgets tighten. MDR remains a slow and expensive path for any monitoring platform that crosses into clinical decision-making, and notified-body capacity is still a bottleneck; a buyer that inherits an incomplete MDR file is buying a liability as well as an asset. Finally, the consumer-wearable buyers may prove fickle if their own growth slows, so a strategy that relies on them as the exit route is riskier than one built around medtech.
8. Pharmacy, medication management and e-prescribing
Germany's electronic prescription has turned pharmacy technology from a sleepy category into one of Europe's most active, and 2027 is when the second-order deals arrive. Redcare Pharmacy, the Shop Apotheke owner, reported prescription growth of 98% in Germany for 2025 and passed a €3 billion annualised revenue run-rate in Q1 2026 with 14 million active customers. DocMorris, its Swiss-listed rival, saw its shares rise almost 150% from March 2026 lows as prescription volumes accelerated to over 80% growth, helped by a July 2026 rule letting chronically ill patients receive repeat prescriptions without a doctor's visit and by Gematik's simpler proof-of-presence standard. Online penetration of the German prescription market is still estimated at low single digits, which is the whole point: the runway is long and the capital to run down it is now available.
Why buyers want in. The e-prescription unlocks a chain of adjacent software markets that were previously constrained by paper. Medication-management apps, adherence platforms, pharmacy-to-patient messaging, prescription-routing middleware and clinical pharmacy services in hospitals all become more valuable once the prescription itself is a digital object that can be routed, reminded, refilled and analysed. France, Austria, Spain and the Nordics are at different stages of the same transition, and the EHDS makes e-prescription and e-dispensation exchange across borders mandatory from March 2029. Pharmacy is also where consumer health and clinical health meet, so the online-pharmacy leaders, the consumer-telehealth platforms and the wholesalers are all converging on the same territory.
Who the acquirers are. The online pharmacies themselves are serial acquirers; Redcare's history includes buying Smartpatient and MedApp for medication management and Farmaline for geographic reach, and DocMorris built its TeleClinic telehealth arm by acquisition. As DocMorris approaches EBITDA break-even and free-cash-flow positivity in 2027, its balance sheet regains the capacity to buy again. Pharmaceutical wholesalers and pharmacy-services groups (Phoenix, McKesson's European successor businesses, Galenica, the UK multiples' owners) are buying pharmacy-software and dispensing-automation companies to defend margin as online share grows. Consumer-health platforms entering Europe, of which Hims & Hers is the most visible after the Eucalyptus deal, need prescribing and fulfilment licences in each country. And the hospital-IT vendors are acquiring medication-management modules, one of the highest-value clinical safety areas, to round out their EPR offerings.
What will trade. We expect three kinds of deals. Country-specific online pharmacies and licensed mail-order operators in France, Spain, Italy and Central Europe, where the leaders want a foothold before local e-prescription reaches scale. Medication-adherence and pharmacy-engagement software, including the German DiGA-adjacent apps and the patient-facing pharmacy platforms, which trade for their user bases. And clinical medication-management systems for hospitals, including closed-loop e-prescribing and pharmacy automation, which are being bought by the EPR consolidators and by automation-focused medtech groups.
Pricing. Online pharmacy trades on revenue growth and gross-margin trajectory rather than earnings, with the market currently valuing the pan-European leader at a premium to its Germany-focused rival. Software assets in the category trade on ARR, with a premium for anything integrated into the Gematik infrastructure or a national e-prescription rail, since integration is the barrier to entry.
What could go wrong. Pharmacy is politically protected in most of Europe, and community-pharmacy lobbies in Germany, France and Italy remain effective at slowing liberalisation; a legislative reversal on mail-order prescription rules would hit the category hard. Reimbursement margins on prescription drugs are thin and regulated, so profitability depends on scale and on higher-margin OTC baskets, which have been growing more slowly than the prescription business. Any buyer paying a growth multiple is betting that penetration keeps compounding, which has been true so far but is not guaranteed.
9. Revenue cycle, coding, payer and health insurance technology
Europe has never had a revenue-cycle-management market on the American model, and that is exactly why 2027 will be interesting: the pieces of one are being assembled, and buyers who understand the US category are arriving to assemble them. In the US, the category is consolidating at pace; Carlyle combined Knack RCM and EqualizeRCM in May 2026 to create an AI-native billing platform, and Innovaccer bought CaduceusHealth for $66 million to fold claims processing into an AI operations layer. European buyers have noticed that the same problems, coding, claims, prior authorisation, denials and payer reconciliation, exist in Germany's DRG system, the Netherlands' insurer-led model, Switzerland's cantonal reimbursement and the private-hospital sectors of the UK, Spain and Italy, and that almost nobody is solving them at scale.
Why buyers want in. Hospital finances across Europe are under sustained pressure, and the administrative cost of getting paid is one of the few line items that software can shrink without touching clinical staffing. Germany's hospital reform is forcing consolidation and tighter coding discipline; the Dutch insurers are pushing more outcome-based contracts that require better data; the NHS is expanding payment-by-results-style mechanisms alongside block contracts; and private insurers everywhere want claims automation to keep loss ratios in check as medical inflation runs above general inflation. Every one of those pressures creates demand for coding automation, claims-processing software and payer-provider data exchange, and generative AI has made the coding piece tractable in languages other than English for the first time.
Who the acquirers are. US revenue-cycle and payer-technology companies, several of them sponsor-owned and needing international growth stories, are the most obvious buyers of European coding, billing and claims-software businesses. Insurance-technology consolidators, both the specialist health-insurance platform vendors and the broader insurance-software groups, will buy the claims and policy-administration systems that serve Europe's private insurers. The hospital-IT vendors described earlier will buy billing and coding modules, as they always have, since revenue-cycle functionality is a core requirement in every EPR tender. And the large German and Dutch health insurers, along with the UK's private medical insurers, are increasingly acquiring or taking stakes in claims-automation, fraud-detection and care-navigation technology rather than licensing it.
What will trade. Clinical-coding automation companies, especially those with validated German, French, Dutch and Nordic language models and hospital reference customers, will be the most contested assets. Payer-side claims and policy-administration platforms serving private health insurers in Germany, the Netherlands, Switzerland and the UK are natural targets for both insurance-software groups and sponsors. Patient-financing and self-pay collection tools for private hospitals and clinics, a small but growing category as out-of-pocket spending rises, will be bought by the private-hospital operators and their payment-processing partners. And care-navigation and benefits-administration platforms serving corporate health schemes, which are booming in the UK and Germany, will attract both insurers and the broker-technology consolidators.
Pricing. This is the category where European valuations are most likely to be pulled up by US benchmarks, because the buyers are often US-owned and think in US multiples. Coding-automation businesses with proven accuracy in non-English languages will trade at a premium to generic healthtech SaaS. Payer-administration systems trade like insurance software, on EBITDA, with a premium for cloud-native platforms and a heavy discount for legacy code bases that require re-platforming.
What could go wrong. The European market is fragmented by design: each country's reimbursement rules are different, so a coding engine built for Germany's DRG system has limited value in France, and a buyer expecting US-style scale economics will be disappointed. Public-sector procurement is also slow and price-sensitive, which caps growth for anything sold to statutory systems. The best assets in this category will be those serving private hospitals and insurers, where the buyer's economics are clearer and the sales cycles shorter.
10. Care operations, workforce and primary care software
The last of our ten is the one most likely to be underestimated, because it is made up of many small, profitable, unfashionable software businesses rather than a few large stories, and that is exactly the profile mid-market private equity is built to consolidate. The category spans practice-management systems for GPs, dentists, physiotherapists and veterinary-adjacent clinics; scheduling, rostering and workforce-management tools for hospitals and care homes; patient-engagement, booking and communication platforms; social-care and home-care management software; and the supply-chain and asset-management tools that keep hospitals running. In the US, the pattern is already visible: staffing-platform mergers such as SnapCare and connectRN and IntelyCare and CareRev in 2026, and sponsor-backed carve-outs such as Veritas Capital's majority stake in GHX, the hospital supply-chain platform. Europe is a few years behind and considerably more fragmented, which is where the returns are.
Why buyers want in. Workforce is the binding constraint on every European health system, and software that squeezes more capacity out of the same clinicians, through better rostering, less administration and fewer missed appointments, has a clearer return on investment than almost anything else in healthtech. The businesses that sell it typically have high renewal rates, modest churn and pricing power, since switching a practice-management or rostering system is disruptive. Many are founder-owned, sub-scale and country-specific, which makes them ideal buy-and-build components. And Doctolib's evolution from a booking platform into a multi-product practice operating system, which triggered the French Competition Authority's abuse-of-dominance ruling in November 2025, has shown both the size of the prize and the regulatory ceiling on organic dominance, which pushes the next wave of growth toward acquisition of adjacent categories rather than deeper penetration of one.
Who the acquirers are. Mid-market and lower-mid-market sponsors are the dominant buyers, typically building a platform in one vertical (dental software, physiotherapy software, care-home management, GP systems) and one country, then bolting on peers across borders. The pan-European practice-software leaders, including CompuGroup Medical under CVC, Doctolib and the UK primary-care vendors, will keep buying adjacent modules. Workforce-management and HR-software groups from outside healthcare see clinical rostering as a specialised, high-margin niche and periodically buy into it. And the care-home and home-care operators, many of them sponsor-owned, are increasingly acquiring the software they depend on, following the vertical-integration pattern seen in US home-based care.
What will trade. Expect a high volume of transactions below €100 million: national practice-management vendors in dental, allied-health and veterinary-adjacent clinics; clinical rostering and bank-staff platforms, especially those with NHS trust or German hospital contracts; social-care and home-care software, a category that is being consolidated in the UK and the Nordics and is about to be in Germany; patient-communication and appointment-management tools; and hospital supply-chain and asset-tracking software, where the European market is fragmented and a GHX-style platform play is plausible. A handful of larger deals is likely too, most obviously a secondary sale or IPO of one of the sponsor-owned vertical-software platforms built during 2022 to 2025.
Pricing. This is EBITDA territory. Scaled vertical-software platforms with 80% or higher recurring revenue trade in the high teens on EBITDA in competitive processes; sub-scale bolt-ons trade at single-digit multiples, which is where the arbitrage lies. Assets serving public-sector customers are discounted for procurement risk; those serving private clinics and care operators are not.
What could go wrong. The risk here is not demand but execution. Buy-and-build works only if the platform integrates its acquisitions, and healthcare software is notoriously hard to integrate because of local regulatory, language and workflow differences. Sponsors that pay platform multiples for a collection of un-integrated country businesses will find exits harder in 2028 than they expected. The other risk is that generative AI erodes the value of some administrative software (scheduling assistants, patient-communication tools) faster than the incumbents can adapt, which would make some of the cheaper-looking bolt-ons cheap for a reason.
What cuts across all ten: buyers, prices, regulation and the risks to the thesis
Standing back from the individual markets, five patterns run through the whole list and will shape how 2027 actually plays out.
Strategic buyers are back, and they are often American. The 2021 cycle was dominated by venture and growth capital; the 2026 cycle is dominated by strategics with cash flow. Hims & Hers, RadNet, Sword Health, Radiology Partners, Universal Health Services and Oura all bought European or Europe-exposed assets in the first eight months of 2026. Their motivation is consistent: Europe has CE-marked, reimbursed, multilingual products at prices below US equivalents, and the regulatory files those products carry are portable. That cross-border demand will persist into 2027 and will set the price for the best assets in most of the ten categories. European strategics, notably the sponsor-owned hospital-IT groups, the online pharmacies and the Nordic provider groups, are the second buyer wave, generally more price-disciplined and more focused on bolt-ons.
Private equity is deploying into platforms, not point solutions. Sponsor buyouts in European healthcare reached a record in 2025, and the funds raised on the back of that activity now have to be invested. The healthtech deals sponsors do in 2027 will mostly be secondary buyouts of scaled platforms, take-privates of listed vendors trading at discounts to private-market values, and carve-outs from diversified groups, with a long tail of bolt-ons executed by the platforms they already own. Sponsors will largely avoid pre-profit clinical-AI and digital-therapeutics companies except as minority growth investments; those assets go to strategics.
Valuation has shifted from revenue growth to profitable growth. Advisers describe the shift as a move toward a profit-weighted 'Rule of 40', and the deals bear that out. A company growing 40% and burning cash will get a lower multiple than one growing 25% at break-even, unless it holds a regulatory or reimbursement asset a strategic cannot replicate. Founders who internalise this in 2026 will get better outcomes in 2027 than those still pricing off 2021 comparables. The other structural change in pricing is the premium for regulatory and reimbursement position: a DiGA listing, a CE Class IIb mark, a national framework contract or an EHDS-ready interoperability certification are each now worth a measurable multiple turn.
Regulation is the calendar, not the obstacle. Three regimes matter most. EHDS, whose implementing acts fall due in March 2027 with the first mandatory data exchanges in March 2029, converts interoperability into a purchasing criterion and gives every vendor a two-year window to become compliant or be acquired by someone who is. The AI Act's obligations for high-risk systems, which include most medical-device AI, raise fixed compliance costs and therefore favour scale, which is an argument for consolidation in categories one, two and seven. And the MDR transition, still grinding through notified-body capacity constraints, remains the single most common source of diligence surprises; buyers in 2027 will price MDR status explicitly, and sellers should have their technical files in order before launching a process. In the UK, the MHRA's international reliance route is a modest tailwind, making CE-marked assets easier to take across the Channel.
Antitrust is a live constraint on platform buyers. The French Competition Authority's November 2025 ruling against Doctolib was notable less for the size of the fine than for the signal: dominant healthtech platforms will be scrutinised for below-threshold acquisitions and for bundling. That pushes the largest European platforms toward adjacent-category acquisitions rather than horizontal ones and makes some of the most obvious consolidation moves in primary-care and booking software harder to execute. It also raises the value of being the second or third player, since those are the companies dominant platforms can no longer simply buy.
What could derail the thesis. Three things. First, macro: a sharp rise in rates or a credit-market shock would hit the sponsor-led half of this forecast quickly, since much of it depends on leverage being available at acceptable cost. Second, policy: European health budgets are tight, and reimbursement reversals in Germany (DiGA, telemonitoring, mail-order pharmacy) or procurement pauses in the NHS would remove the demand signal behind several categories at once. Third, technology: the pace of general-purpose AI improvement is such that some software categories, particularly administrative tools and first-generation clinical AI, could be commoditised faster than acquirers expect, which would turn strategic premiums into write-downs. None of these seems likely enough to change the direction of travel, but each is worth a line in every investment memo.
Conclusion: what to watch in 2027
If 2026 was the year European healthtech M&A recovered its nerve, 2027 is set up to be the year it recovers its volume. The ten markets above share a common structure: a demand driver rooted in workforce shortage or regulatory deadline, a supply of sub-scale companies that cannot fund the next stage alone, and a buyer set with cash and a reason to move now. Where those three align most tightly, in ambient AI, imaging AI, hospital core systems and health data, we expect the most activity and the highest prices. Where the buyer set is broadest, in virtual care, monitoring, pharmacy and care operations, we expect the most deals by count. Digital therapeutics and revenue-cycle technology are the two categories where 2027 could surprise, in opposite directions: DTx because consolidation may be driven by distress, and revenue cycle because US buyers may import valuations Europe has not seen before.
For founders and boards, the practical implication is to spend the rest of 2026 on the things that acquirers will pay for in 2027: a clean MDR and AI Act position, a credible EHDS roadmap, reimbursement in more than one country, and a path to profitability that does not depend on the next funding round. For investors, the implication is to be early to the categories where consolidation is inevitable but has not yet started, and to be disciplined in the ones where a public benchmark has already anchored seller expectations.
Six signals will tell us during the year whether this forecast is holding:
Whether the Commission publishes the EHDS implementing acts on time in March 2027, and how prescriptive they are about EHR certification.
Whether Ardian launches a Dedalus process, which would be the year's bellwether transaction for hospital IT.
How many of the scribe consolidators announce a second or third country acquisition, and whether any incumbent EHR vendor buys one outright.
Whether the German DiGA reforms produce a visible wave of delistings and portfolio sales in the first half of the year.
Whether a second US strategic follows Hims & Hers into European consumer prescribing at a comparable price.
Whether a scaled European imaging-AI platform is acquired by a scanner manufacturer rather than a services group, which would mark a shift in who controls distribution.
If four or more of those come through, 2027 will have been the year European healthtech M&A finally matched the size of the opportunity. If fewer do, the deals will still happen, just a year later and at lower prices, which is a reminder that in this market timing is a variable, but direction is not.
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Healthcare.Digital serves as a research platform for Nelson Advisors’ perspectives on deals, valuations and structural shifts reshaping Global Digital Health, MedTech, Healthcare AI and Health IT. https://www.healthcare.digital
Nelson Advisors is one of Europe's leading mergers and acquisitions advisory firms, exclusively dedicated to the dynamic and rapidly evolving healthcare technology sector. With a deep understanding of market dynamics and technological advancements, they empower innovative HealthTech companies and strategic investors to navigate complex transactions and achieve their growth ambitions. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #Genomics
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments